QPPV.COM KNOWLEDGE ASSESSMENT

Ranibizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Ranibizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why was a Fab fragment considered suitable for intravitreal use?

Its smaller size was intended to support retinal penetration and its lack of Fc avoids unnecessary effector functions Its Fc region prolongs systemic exposure and provides sustained retinal immunosuppression Its bivalent structure allows it to cross-link VEGF receptors and desensitise them Its enzymatic activity directly removes fluid from the vitreous cavity

Question 2 of 10 What is the main pharmacovigilance significance of same-day bilateral intravitreal treatment?

It eliminates the need to record laterality because both eyes receive treatment It increases exposure in one encounter and creates two procedure sites that should be separately evaluated It proves that systemic adverse events are caused by ranibizumab It makes product and batch information unnecessary

Question 3 of 10 How should arterial thromboembolic events after intravitreal ranibizumab generally be framed in pharmacovigilance assessment?

They should automatically be considered caused by ranibizumab They should be dismissed because intravitreal treatment has no systemic exposure They should be monitored as a potential class risk while considering timing and substantial baseline cardiovascular risk They should be classified as injection-site reactions

Question 4 of 10 Why is recording only 'ranibizumab' insufficient when authorised biosimilars are used?

Biosimilars have a different pharmacological target The INN alone cannot identify the exact biological product and batch needed for traceability Biosimilars cannot be evaluated in routine pharmacovigilance The reference product has no batch number

Question 5 of 10 A patient with diabetic macular oedema improves anatomically after ranibizumab, but the underlying diabetes remains poorly controlled. Which interpretation is most appropriate?

Ranibizumab has corrected the systemic metabolic cause of diabetes The response is inconsistent with the mechanism of ranibizumab Ranibizumab has reduced a major mediator of vascular leakage without treating the systemic cause The improvement proves that VEGF is the only cause of diabetic retinal disease

Question 6 of 10 What is the most appropriate approach to pregnancy exposure following intravitreal ranibizumab?

Assume there is no fetal exposure because the route is local Assume any pregnancy outcome is caused by ranibizumab because VEGF has developmental roles Document exposure carefully while recognizing both low systemic exposure and the theoretical developmental relevance of VEGF Exclude the case from pharmacovigilance because pregnancy was not the indication

Question 7 of 10 Why should a pharmacovigilance assessment distinguish infectious endophthalmitis from sterile intraocular inflammation?

They have identical causes and require identical treatments The distinction affects clinical management, case interpretation and potential product or procedural investigations Sterile inflammation is never clinically serious Microbiology is irrelevant in both conditions

Question 8 of 10 Which statement best reflects appropriate assessment of suspected immunogenicity with ranibizumab?

A positive anti-drug antibody test alone proves clinically relevant immunogenicity Immunogenicity should be considered using antibody results together with inflammation, loss of response, hypersensitivity, timing and assay context Immunogenicity is impossible because ranibizumab is a Fab fragment Only systemic allergic symptoms are relevant to immunogenicity

Question 9 of 10 What is the principal pharmacological action of ranibizumab in retinal disease?

It destroys abnormal endothelial cells through antibody-dependent cellular cytotoxicity It stimulates retinal pigment epithelial regeneration It binds VEGF-A and prevents activation of endothelial VEGF receptors It blocks glucose uptake by retinal endothelial cells

Question 10 of 10 Which presentation should prompt urgent evaluation for possible post-injection endophthalmitis?

A small, painless subconjunctival haemorrhage with stable vision Eye pain, worsening redness, photophobia and reduced vision after injection A stable pre-existing refractive error Mild transient awareness of the eye immediately after topical anaesthesia

Ranibizumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings